Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on February 28, 2007, and March 1, 2007, for Protalix Biotherapeutics, Inc. (formerly Protalix Ltd.). The Company is a biotechnology firm incorporated in Florida with principal executive offices in Carmiel, Israel, and Miami, Florida.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses on corporate governance, executive compensation, and branding changes.
Material Changes and Corporate Actions
- Stock Option Amendments: The Board amended Stock Option Award Agreements for Phillip Frost, M.D., Jane Hsiao, Ph.D., and Steven Rubin. The new vesting schedule requires 40% of options to vest on March 1, 2008, with the remaining 60% vesting in four 15% increments through September 30, 2009.
- Executive Appointment: Protalix Ltd. (a wholly-owned subsidiary) appointed Iftah Katz as Vice President of Operations effective February 28, 2007. His compensation includes a monthly salary of NIS 45,000 (approx. $10,672 USD) and an option to purchase 204,351 shares of common stock, vesting over four years.
- Corporate Name and Ticker Change: Effective March 1, 2007, the Company changed its name to Protalix BioTherapeutics, Inc. The ticker symbol on the OTC Bulletin Board changed to PXTB.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding future financial performance or operational outlook. The document strictly reports on the execution of the aforementioned agreements and the name change.
Key Facts for Investor Verification
- Verify the new ticker symbol PXTB on the OTC Bulletin Board.
- Confirm the dilution impact of the 204,351 stock options granted to the new Vice President of Operations.
- Review the revised vesting schedules for existing options held by directors and consultants to assess future equity dilution.
- Check subsequent filings for the specific exercise price of the options granted to Mr. Katz, as it was to be determined by the Compensation Committee.